DENİZ CAN GUVEN, OKTAY HALİT AKTEPE, HASAN CAGRİ YİLDİRİM, ISMAİL CELİK, SAADETTİN KILIÇKAP
Eurasian Journal of Medical Investigation - 2021;5(3):409-413
Objectives: Peripheral blood-based markers like the systemic inflammation index is (SII) could be valuable for mela noma patients treated with immune checkpoint inhibitors (ICIs), although the data is limited. We aimed to evaluate the association between the baseline SII with survival in ICI-treated melanoma patients. Methods: The data of 44 advanced adult melanoma patients treated with ICIs (ipilimumab or nivolumab) were retro spectively evaluated. The SII was calculated with the platelet*(neutrophil/lymphocyte) formula. The median value of SII as the cut-off point. The association between SII values and survival were evaluated with univariate and multivariate analyses. Results: The median age was 61 years (IQR 51-68), and 52.3% of the patients were male. During a median follow-up of 7.52 months, 35 patients died (79.5%), and 39 patients (88.6%) had any PFS event. The patients with higher SII val ues had decreased overall survival (OS) (11.203±2.491 vs. 5.520±2.063 months, p=0.015). In the multivariate analyses, including adjustments according to patient sex, age, and lactate dehydrogenase levels, patients with higher SII values had decreased OS (HR: 2.209, 95% CI: 1.105-4.417, p=0.025). Conclusion: In our experience, melanoma patients with higher SII values had poorer survival. The SII could be a valu able biomarker for prognosis estimation in ICI-treated melanoma patients.
